Silicosis Prevention and Treatment Act
- Sponsor
- Rep. Correa, J. Luis [D-CA-46]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Oct 13, 2026
Bottom line
This bill creates a new federal grant program to support health services and education aimed at preventing and treating silicosis, a severe lung disease, for affected workers and communities.
What it actually does
This bill establishes a competitive grant program within the Department of Health and Human Services, administered by the Health Resources and Services Administration. The program aims to fund eligible healthcare entities to provide treatment for individuals with silicosis, regardless of their ability to pay, and to offer education to workers in industries with high silica exposure. It authorizes $10 million annually for fiscal years 2027 through 2031.
Proponents argue
Supporters would argue that this bill addresses a critical public health need by providing dedicated funding for a debilitating occupational disease. It ensures that vulnerable workers receive necessary care and education, promotes early detection and prevention, and offers a targeted approach to a specific health crisis that may not be adequately covered by general health programs.
Opponents contend
Critics might argue that while the intent is commendable, creating a new, narrowly focused grant program could add to federal bureaucracy and potentially be less efficient than integrating silicosis care into existing broader occupational health or public health programs. Some may also question the specific funding level or the competitive grant structure as potentially insufficient or inequitable.
The bill is very short and clearly written, making it highly accessible for any reader to understand its core provisions quickly and thoroughly.
Section 2(a)
Establishment of Silicosis Clinics Grant Program
This section directs the Secretary of Health and Human Services, through the Health Resources and Services Administration, to create a competitive grant program. The grants will be awarded to eligible healthcare entities to provide treatment for individuals with silicosis, regardless of their ability to pay, and to offer education to workers in industries at high risk of silica exposure.
Supporters argue
Supporters argue this program is crucial for addressing a specific, severe occupational disease that often affects underserved populations. It provides a dedicated funding stream to ensure specialized care and preventative education, which may not be adequately covered by general health programs.
Critics contend
Critics might contend that creating a new, disease-specific grant program could lead to fragmentation of healthcare services and administrative overhead. They might suggest that existing public health or occupational safety programs could be expanded or better funded to cover silicosis, rather than establishing a separate mechanism.
Tradeoffs
The bill balances the need for targeted intervention for a specific disease with the potential for creating a new, specialized program rather than integrating into broader health initiatives. It also balances competitive funding, which rewards strong proposals, with ensuring equitable access across all affected regions.
Section 2(c)
Permitted Uses of Grant Funds
This section specifies how the grant money can be used by eligible entities. It includes activities such as public awareness campaigns, screening, diagnosis, and treatment for silicosis, educational programs for patients and workers, counseling on benefits, patient care coordination, and pulmonary rehabilitation. The Secretary can also approve other related activities.
Section 2(e)
Funding Authorization
This section authorizes the appropriation of $10,000,000 for each of the fiscal years 2027 through 2031 to carry out the silicosis clinics program. This means Congress can choose to allocate up to this amount annually for five years, totaling $50 million over the period, but does not mandate the actual appropriation.